ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan’s Kaneka has formed a joint venture with MedRx, a research and development firm based on the Japanese island of Shikoku that is developing ionic-liquid-based systems for delivering drugs through the skin. The new venture, owned 51% by Kaneka and 49% by MedRx, will take over programs that MedRx is now developing on its own. Kaneka will contribute cash and expertise in polymer technology. The partners expect that their venture will achieve annual sales of $55 million within five years. MedRx is conducting Phase I human trials of a system for delivering the anti-inflammatory drug etodolac.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter